Retina TodayVigabatrin-Related Retinal Toxicity

Vigabatrin, an antiepileptic medication used for refractory focal epilepsy and infantile spasms, is associated with retinal toxicity that can cause irreversible visual field loss. Although many patients remain asymptomatic, toxicity may develop months to years after treatment initiation and can lead to significant functional vision impairment if not detected early.

Clinical Considerations

• Vigabatrin‑associated visual field loss (VAVFL) typically presents as bilateral concentric peripheral field constriction.
• Reported prevalence averages ~52% in adults and ~34% in children, with many cases remaining asymptomatic until advanced.
• Retinal toxicity has been reported as early as weeks after initiation, though average onset ranges from 6 months to 5 years.
• OCT findings may include ganglion cell layer–inner plexiform layer thinning, while mfERG often shows peripheral cone dysfunction, even when visual acuity remains intact.

Practice Applications

• For ophthalmologists and retina specialists: Maintain ongoing surveillance for patients receiving vigabatrin, even with preserved acuity and normal fundus appearance.
• For optometrists: Be alert to subtle functional complaints (navigation difficulty, peripheral awareness) and refer promptly for perimetry and retinal evaluation.
• For multidisciplinary care teams: Coordinate closely with neurology when retinal toxicity is suspected, as discontinuation may stabilize but not reverse vision loss.
• Across settings: Incorporate OCT and mfERG when standard perimetry is unreliable, especially in pediatric or cognitively impaired patients.

More in Drug Safety & Interactions